{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:36:04Z","timestamp":1782862564738,"version":"3.54.5"},"reference-count":74,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.dld.2021.04.028","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T16:49:37Z","timestamp":1621183777000},"page":"1531-1538","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Treatment of primary sclerosing cholangitis"],"prefix":"10.1016","volume":"53","author":[{"given":"Annarosa","family":"Floreani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2021.04.028_bib0001","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cld.2015.08.005","article-title":"Primary sclerosing cholangitis: multiple phenotypes, multiple approaches","volume":"20","author":"Sarkar","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2021.04.028_bib0002","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.mayocp.2015.03.017","article-title":"The cholangiopathies","volume":"90","author":"Lazaridis","year":"2015","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.dld.2021.04.028_bib0003","article-title":"Management of primary sclerosing cholangitis and its complications: an algorithmic approach","author":"Prokopi\u010d","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.dld.2021.04.028_bib0004","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","article-title":"New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and Beyond","volume":"62","author":"Beuers","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.dld.2021.04.028_bib0005","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"ursodiol for primary sclerosing cholangitis. Mayo primary sclerosing cholangitis-ursodeoxycholic acid study group","volume":"336","author":"Lindor","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.028_bib0006","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"Olsson","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.028_bib0007","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"Lindor","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0008","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"Wunsch","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0009","article-title":"Bile acids for primary sclerosing cholangitis","author":"Proropat","year":"2011","journal-title":"Cochrane Datab Syst Rev"},{"key":"10.1016\/j.dld.2021.04.028_bib0010","article-title":"The association of UDCA treatment with long-term outcome and biliary tract outcome and biliary cancer in patients with primary sclerosing cholangitis","author":"Arizumi","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0011","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/hep.22891","article-title":"Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-\/- mice","volume":"49","author":"Halilbasic","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0012","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1053\/j.gastro.2005.10.018","article-title":"24-norursodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice","volume":"130","author":"Fickert","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.028_bib0013","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","article-title":"NorUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis","volume":"67","author":"Fickert","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0014","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.028_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3389\/fmed.2020.00117","article-title":"New therapeutic targets in autoimmune cholangiopathies","volume":"7","author":"Gerussi","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.dld.2021.04.028_bib0016","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1053\/j.gastro.2011.10.028","article-title":"Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis","volume":"142","author":"Modica","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.028_bib0017","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jhep.2020.02.033","article-title":"A Randomized, placebo-controlled, phase ii study of obeticholic acid for primary sclerosing cholangitis","volume":"73","author":"Kowdley","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0018","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1194\/jlr.M005546","article-title":"Retinoic acid represses CYP7A1 expression in human hepatocytes and HepG2 cells by FXR\/RXR-dependent and independent mechanisms","volume":"51","author":"Cai","year":"2010","journal-title":"J Lipid Res"},{"key":"10.1016\/j.dld.2021.04.028_bib0019","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/hep.24047","article-title":"Combination of retinoic acid and ursodeoxycholic acid attenuates liver injury in bile duct-ligated rats and human hepatic cells","volume":"53","author":"He","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0020","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1097\/MCG.0000000000000591","article-title":"Combination therapy of all-trans retinoic acid with ursodeoxycholic acid in patients with primary sclerosing cholangitis: a human pilot study","volume":"51","author":"Assis","year":"2017","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.028_bib0021","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9010060","article-title":"The non-steroidal FXR agonist cilofexor improves portal hypertension and reduces hepatic fibrosis in a rat NASH model","volume":"9","author":"Schwabl","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.dld.2021.04.028_bib0022","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1002\/hep.30509","article-title":"The nonsteroidal farnesoid X receptor agonist Cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis","volume":"70","author":"Trauner","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0023","doi-asserted-by":"crossref","first-page":"185","DOI":"10.18097\/pbmc20206603185","article-title":"The inhibitors of the apical sodium-dependent bile acid transporter (ASBT) as promising drugs","volume":"66","author":"Saveleva","year":"2020","journal-title":"BIOMED KHIM"},{"key":"10.1016\/j.dld.2021.04.028_bib0024","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.jhep.2015.10.024","article-title":"Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis","volume":"64","author":"Baghdasaryan","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0025","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/hep.27973","article-title":"Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice","volume":"63","author":"Miethke","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0026","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/hep.26894","article-title":"Peroxisome proliferator-activated receptor \u03b1 activates human multidrug resistance transporter 3\/ATP-binding cassette protein subfamily B4 transcription and increases rat biliary phosphatidylcholine secretion","volume":"59","author":"Ghonem","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0027","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0028","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A Placebo-Controlled trial of Bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dld.2021.04.028_bib0029","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0016-5085(19)32419-9","article-title":"Effects of Clofibrate in primary biliary cirrhosis hypercholesterolemia and gallstones","volume":"69","author":"Summerfield","year":"1975","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.028_bib0030","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s00535-010-0204-x","article-title":"Bezafibrate for the treatment of primary sclerosing cholangitis","volume":"45","author":"Mizuno","year":"2010","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.028_bib0031","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/jhbp.281","article-title":"Prospective study of bezafibrate for the treatment of primary sclerosing cholangitis","volume":"22","author":"Mizuno","year":"2015","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"10.1016\/j.dld.2021.04.028_bib0032","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: french-spanish experience","volume":"42","author":"Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.028_bib0033","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.028_bib0034","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.25748","article-title":"Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions","volume":"56","author":"Kremer","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0035","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/hepr.12846","article-title":"Factors predictive of the efficacy of bezafibrate therapy in patients with primary sclerosing cholangitis: factors predictive of bezafibrate efficacy in PSC","volume":"47","author":"Mizuno","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.dld.2021.04.028_bib0036","first-page":"S1028","article-title":"Fenofibrate improves alkaline phosphatase in primary sclerosing cholangitis","volume":"144","author":"Dejman","year":"2013","journal-title":"Gastroenterology 2013"},{"key":"10.1016\/j.dld.2021.04.028_bib0037","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/hep.26993","article-title":"Cholangiocyte senescence by way of N-ras activation is a characteristic of primary sclerosing cholangitis","volume":"59","author":"Tabibian","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0038","first-page":"hep4.1619","article-title":"Efficacy and safety of cenicriviroc in patients with primary sclerosing cholangitis: PERSEUS study","author":"Eksteen","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.dld.2021.04.028_bib0039","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1097\/00042737-199907000-00015","article-title":"Immunohistochemical analysis of inflammation in primary sclerosing cholangitis","volume":"11","author":"Ponsioen","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0040","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cgh.2019.05.013","article-title":"Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases","volume":"18","author":"Lynch","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0041","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/apt.14525","article-title":"Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease","volume":"47","author":"Christensen","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.028_bib0042","doi-asserted-by":"crossref","unstructured":"Lin, B.C.; Desnoyers, L.R. FGF19 and Cancer. In Endocrine FGFs and klothos; Kuro-o, M., editor; Advances in Experimental Medicine and Biology; Springer US: New York, NY, 2012; Vol. 728, pp. 183\u2013194 ISBN 978-1-4614-0886-4.","DOI":"10.1007\/978-1-4614-0887-1_12"},{"key":"10.1016\/j.dld.2021.04.028_bib0043","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jhep.2018.10.035","article-title":"Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: a multicenter, randomized, double-blind, placebo-controlled phase II trial","volume":"70","author":"Hirschfield","year":"2019","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0044","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1152\/physrev.00044.2005","article-title":"The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology","volume":"87","author":"Bedard","year":"2007","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.dld.2021.04.028_bib0045","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.3390\/nu12061576","article-title":"Oxidative stress management in chronic liver diseases and hepatocellular carcinoma","volume":"12","author":"Uchida","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.dld.2021.04.028_bib0046","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/j.gastro.2015.04.009","article-title":"Hepatocyte nicotinamide adenine dinucleotide phosphate reduced oxidase 4 regulates stress signaling, fibrosis, and insulin sensitivity during development of steatohepatitis in mice","volume":"149","author":"Bettaieb","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.dld.2021.04.028_bib0047","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.cgh.2018.11.002","article-title":"Statin use is associated with improved outcomes of patients with primary sclerosing cholangitis","volume":"17","author":"Stokkeland","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0048","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/hep.21741","article-title":"Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid","volume":"46","author":"Stojakovic","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0049","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1136\/gutjnl-2016-312473","article-title":"Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal","volume":"66","author":"Ikenaga","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.04.028_bib0050","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/nm.2208","article-title":"Allosteric Inhibition of lysyl oxidase\u2013like-2 impedes the development of a pathologic microenvironment","volume":"16","author":"Barry-Hamilton","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.dld.2021.04.028_bib0051","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1111\/liv.13177","article-title":"Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial","volume":"36","author":"Meissner","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.dld.2021.04.028_bib0052","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S0168-8278(17)30370-7","article-title":"Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials","volume":"66","author":"Sanyal","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.dld.2021.04.028_bib0053","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.30237","article-title":"Simtuzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease","volume":"69","author":"Muir","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0054","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/gutjnl-2015-311004","article-title":"Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD","volume":"65","author":"Sabino","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.04.028_bib0055","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/gutjnl-2015-310500","article-title":"The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls","volume":"66","author":"Kummen","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.04.028_bib0056","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/apt.15375","article-title":"Consistent alterations in faecal microbiomes of patients with primary sclerosing cholangitis independent of associated colitis","volume":"50","author":"R\u00fchlemann","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.028_bib0057","doi-asserted-by":"crossref","first-page":"814","DOI":"10.14309\/ajg.0000000000000604","article-title":"Targeting the gut microbiome as a treatment for primary sclerosing cholangitis: a conceptional framework","volume":"115","author":"Shah","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.028_bib0058","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jhep.2020.01.017","article-title":"Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis","volume":"72","author":"Bajaj","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0059","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2017.05.007","article-title":"Targeting the gut-liver axis in liver disease","volume":"67","author":"Wiest","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.dld.2021.04.028_bib0060","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1136\/gutjnl-2018-317993","article-title":"British society of gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis","volume":"68","author":"Chapman","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.04.028_bib0061","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/hep.20457","article-title":"Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial","volume":"40","author":"F\u00e4rkkil\u00e4","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0062","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ajg.2008.14","article-title":"Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study","volume":"104","author":"Silveira","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.028_bib0063","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study","volume":"37","author":"Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.dld.2021.04.028_bib0064","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1136\/gutjnl-2018-316599","article-title":"Oral vancomycin induces clinical and mucosal remission of colitis in children with primary sclerosing cholangitis\u2013ulcerative colitis","volume":"68","author":"Tan","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.dld.2021.04.028_bib0065","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis","volume":"73","author":"Deneau","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0066","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/21678707.2020.1865917","article-title":"Gut microbial profiling as a therapeutic and diagnostic target for managing primary biliary cholangitis","volume":"8","author":"Floreani","year":"2020","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.dld.2021.04.028_bib0067","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.14309\/ajg.0000000000000115","article-title":"Fecal microbiota transplantation in patients with primary sclerosing cholangitis: a pilot clinical trial","volume":"114","author":"Allegretti","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.028_bib0068","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cld.2015.08.008","article-title":"Sclerosing cholangitis in children and adolescents","volume":"20","author":"Mieli-Vergani","year":"2016","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.dld.2021.04.028_bib0069","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"European association for the study of the liver EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.dld.2021.04.028_bib0070","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1111\/j.1572-0241.2005.41841.x","article-title":"Clinical course and outcome of autoimmune hepatitis\/primary sclerosing cholangitis overlap syndrome","volume":"100","author":"Floreani","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.dld.2021.04.028_bib0071","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jhep.2010.09.002","article-title":"International autoimmune hepatitis group overlap syndromes: the international autoimmune hepatitis group (IAIHG) position statement on a controversial issue","volume":"54","author":"Boberg","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2021.04.028_bib0072","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/hep.23294","article-title":"Diagnosis and management of primary sclerosing cholangitis","volume":"51","author":"Chapman","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0073","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1002\/hep.28256","article-title":"Surrogate endpoints for clinical trials in primary sclerosing cholangitis: review and results from an international psc study group consensus process: hepatology, Vol. XX, No. X, 2015","volume":"63","author":"Ponsioen","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2021.04.028_bib0074","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jhep.2019.06.012","article-title":"Validation, clinical utility and limitations of the amsterdam-oxford model for primary sclerosing cholangitis","volume":"71","author":"Goet","year":"2019","journal-title":"J. Hepatol."}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821002139?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865821002139?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:18:13Z","timestamp":1761625093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865821002139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":74,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S1590865821002139"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2021.04.028","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of primary sclerosing cholangitis","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2021.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l.","name":"copyright","label":"Copyright"}]}}